ARS Pharmaceuticals (SPRY) Operating Margin (2022 - 2025)
Historic Operating Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 163.66%.
- ARS Pharmaceuticals' Operating Margin rose 8879800.0% to 163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.59%, marking a year-over-year increase of 22925600.0%. This contributed to the annual value of 3.46% for FY2024, which is 2250632100.0% up from last year.
- Per ARS Pharmaceuticals' latest filing, its Operating Margin stood at 163.66% for Q3 2025, which was up 8879800.0% from 302.95% recorded in Q2 2025.
- ARS Pharmaceuticals' 5-year Operating Margin high stood at 54.51% for Q4 2024, and its period low was 206030.0% during Q2 2023.
- Over the past 4 years, ARS Pharmaceuticals' median Operating Margin value was 1070.74% (recorded in 2022), while the average stood at 28230.81%.
- Per our database at Business Quant, ARS Pharmaceuticals' Operating Margin plummeted by 2000000000bps in 2023 and then soared by 2000000000bps in 2024.
- Quarter analysis of 4 years shows ARS Pharmaceuticals' Operating Margin stood at 3507.94% in 2022, then crashed by -5773bps to 206030.0% in 2023, then soared by 100bps to 54.51% in 2024, then plummeted by -400bps to 163.66% in 2025.
- Its last three reported values are 163.66% in Q3 2025, 302.95% for Q2 2025, and 466.29% during Q1 2025.